Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000708779 | SCV000837727 | uncertain significance | Cowden syndrome | 2018-07-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000819850 | SCV000960532 | uncertain significance | Gastrointestinal stromal tumor; Paragangliomas 4; Pheochromocytoma | 2023-02-14 | criteria provided, single submitter | clinical testing | This missense change has been observed in individual(s) with clinical features of mitochondrial complex II deficiency (PMID: 27604842, 34490615). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SDHB protein function. ClinVar contains an entry for this variant (Variation ID: 584582). This variant is present in population databases (rs761350633, gnomAD 0.0009%). This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 257 of the SDHB protein (p.Leu257Val). |
Center for Genomic Medicine, |
RCV002268269 | SCV002552218 | pathogenic | not provided | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004659188 | SCV005161196 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-02 | criteria provided, single submitter | clinical testing | The p.L257V variant (also known as c.769C>G), located in coding exon 8 of the SDHB gene, results from a C to G substitution at nucleotide position 769. The leucine at codon 257 is replaced by valine, an amino acid with highly similar properties. This alteration has been identified as homozygous in patients with mitochondrial complex II deficiency (Grønborg S et al. JIMD Rep, 2017 Sep;33:69-77; van der Ven AT et al. Clin Genet, 2021 Dec;100:766-770). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is lexpected to be causative of autosomal recessive mitochondrial complex II deficiency when present along with a second likely pathogenic/pathogenic variant on the other allele; however, its clinical significance in regards to autosomal dominant paraganglioma-pheochromocytoma syndrome is unclear. |
OMIM | RCV001310279 | SCV001500012 | pathogenic | Mitochondrial complex 2 deficiency, nuclear type 4 | 2021-03-08 | no assertion criteria provided | literature only |